Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIP versus TI-CE for relapsed or refractory germ cell tumor
ACTRN12618001236280Phase 3Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, open-label trial of paclitaxel, ifosfamide, cisplatin, carboplatin, etoposide and 1 more in germ cell tumor (GCT), seminoma, non-seminomatous germ cell tumor (NSGCT) and 7 more (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall survival. Started Sep 2018; status: active, not recruiting.
02
Drugs
paclitaxelifosfamidecisplatincarboplatinetoposide
03
Conditions
germ cell tumor (GCT)seminomanon-seminomatous germ cell tumor (NSGCT)teratomachoriocarcinoma
Beyond the preview
Go deeper on ACTRN12618001236280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001236280.